Walgreens Shareholders Greenlight $11.45 Bln Sycamore Buyout

Walgreens Boots Alliance (WBA) shareholders have overwhelmingly approved the planned acquisition by Sycamore Partners, with approximately 96% of all votes and 95% of unaffiliated shareholder votes in favor. Under the terms, WBA investors will receive $11.45 in cash per share, plus a non-transferable right to claim up to an additional $3.00 per share from future proceeds of WBA's stakes in VillageMD's Village Medical, Summit Health, and CityMD businesses. The transaction is on track to close in Q3 or Q4 2025, with WBA shares currently trading near the cash offer price.

Analysis

Walgreens Boots Alliance (WBA) has secured overwhelming shareholder approval for its acquisition by Sycamore Partners, with 96% of total votes and 95% of unaffiliated shareholder votes favoring the deal, effectively removing a key hurdle for the transaction. The deal structure offers investors a fixed component of $11.45 in cash per share, which is marginally below the current trading price of $11.52. The primary source of potential upside is a non-transferable contingent value right (CVR) entitling shareholders to a maximum of an additional $3.00 per share, dependent on the future monetization of WBA's investments in VillageMD, Summit Health, and CityMD. The market's pricing of WBA shares slightly above the cash offer suggests a high probability of deal closure and assigns some, albeit modest, initial value to this CVR. However, the lengthy closing timeline, projected for Q3 or Q4 2025, introduces significant duration risk and uncertainty regarding the final realization of the CVR's value.

Key Decisions for Investors

• Merger arbitrage investors should note the negative spread between the current stock price of $11.52 and the $11.45 cash offer, meaning any potential profit is now solely dependent on the uncertain value of the contingent value right and subject to a long holding period until late 2025.
• Current shareholders must assess their conviction in the successful future monetization of WBA's healthcare assets, as the value of the CVR, worth up to $3.00 per share, is the primary source of potential returns above the established cash consideration.
• Investors considering a position should weigh the high probability of deal closure against the significant duration risk associated with the Q3/Q4 2025 timeline, which exposes the investment to potential market shifts and delays.